Bristol-Myers Squibb buying Celgene in Rs 7400 crores deal
Shareholders of Bristol-Myers Squibb Co, based in New York City, would own about 69 per cent of the company, with Celgene shareholders owning about 31 per cent.
Bristol-Myers Squibb Company (BMS) is an American pharmaceutical company, manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read Also: Bristol-Myers Squibb collaborates with Harvard for new fibrosis research
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at firstname.lastname@example.org Contact no. 011-43720751 To know about our editorial team click here